Open AccessThe cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants
Author(s) -
Randa ElZein,
Carol J. Etzel,
Reginald F. Munden
Publication year - 2018
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2018.05.09
Subject(s) - medicine , micronucleus test , micronucleus , lung cancer , national lung screening trial , cancer , surrogate endpoint , biomarker , lung cancer screening , oncology , lung , pathology , toxicity , genetics , biology
Despite the promising results of the National Lung Screening Trial in reducing lung cancer mortality among high risk smokers, several challenges remain to be addressed. These include the high false positive rates and the large number of smokers screened in order to prevent one lung cancer death. In addition, host genetic susceptibility has not been integrated into selection of who should be screened. These challenges highlight the need to develop robust ways to identify susceptible smokers for appropriate screening.